KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Income from Continuing Operations for 8 consecutive years, with 42923000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 58.96% to 42923000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 437987000.0 through Dec 2025, up 16.09% year-over-year, with the annual reading at 437987000.0 for FY2025, 16.09% up from the prior year.
  • Income from Continuing Operations hit 42923000.0 in Q4 2025 for Vir Biotechnology, up from 163141000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 525254000.0 in Q4 2021 to a low of 213717000.0 in Q3 2024.
  • Historically, Income from Continuing Operations has averaged 26532150.0 across 5 years, with a median of 107773500.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 596.92% in 2021 and later tumbled 223.75% in 2022.
  • Year by year, Income from Continuing Operations stood at 525254000.0 in 2021, then tumbled by 119.34% to 101603000.0 in 2022, then dropped by 14.14% to 115973000.0 in 2023, then grew by 9.82% to 104589000.0 in 2024, then surged by 58.96% to 42923000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VIR at 42923000.0 in Q4 2025, 163141000.0 in Q3 2025, and 110958000.0 in Q2 2025.